WO2004024059A2 - Improved process for preparation of thiazolidinedione derivatives - Google Patents

Improved process for preparation of thiazolidinedione derivatives Download PDF

Info

Publication number
WO2004024059A2
WO2004024059A2 PCT/IB2003/003858 IB0303858W WO2004024059A2 WO 2004024059 A2 WO2004024059 A2 WO 2004024059A2 IB 0303858 W IB0303858 W IB 0303858W WO 2004024059 A2 WO2004024059 A2 WO 2004024059A2
Authority
WO
WIPO (PCT)
Prior art keywords
acid
thiazolidinone
base
ethyl
aliphatic
Prior art date
Application number
PCT/IB2003/003858
Other languages
French (fr)
Other versions
WO2004024059A3 (en
Inventor
Ghanshamlal Lala Rajendra
Narayan Gadkari Parag
Janak Shah Maya
Ramanlal Shah Janak
Original Assignee
Themis Laboratories Private Limited,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Themis Laboratories Private Limited, filed Critical Themis Laboratories Private Limited,
Priority to AU2003260813A priority Critical patent/AU2003260813A1/en
Publication of WO2004024059A2 publication Critical patent/WO2004024059A2/en
Publication of WO2004024059A3 publication Critical patent/WO2004024059A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention provides a novel method for preparation of Thiazoiidinedione derivatives including pioglitazone, cgiitazone, englitazone and rosiglitazone and their pharmaceutically acceptable salts
  • the yields are generally ⁇ 50%.
  • the conversion of the nitrile to aldehyde involves reduction with Raney Nickel alloy in formic acid a reaction that is cumbersome and hazardous.
  • the yield of the reduced product is as low as 30%.
  • the conversion of compound 5 in Scheme-1 i.e. 5-[4-(2-(5-ethyl-2-pyridyl) ethoxy]benzylidene]2.4- thiazolidinedione to Pioglitazone base is effected in DMF as solvent using palladium black catalyst.
  • the reaction requires hydrogen pressure of 50kg/cm 2 and a temperature in the range of 50-60°C.
  • compound represented by formula -7 is prepared by subjecting compound represented by formula-13, to hydrolysis.
  • This reaction is carried out in a solvent using mineral acid.
  • the solvents of choice are alcohols e.g. methanol, ethanol, propanol, butanol, isobutanol, 2-methoxy ethanol etc, dimethyl sulfoxide, sulfolane, dioxane and tetrahydrofuran, dimethoxy ethane etc.
  • the mineral acid used are hydrochloric acid, sulfuric acid, hydrobromic acid, etc.
  • the reaction temperature ranges from 20-150°C with the process taking up to 20 hours.
  • the reaction for producing compound of formula 10 from compound of formula 1 is carried out with sodium hydride and in solvent like dimethyl formamide or tetrahydrofuran at temperatures ranging from -10 to 30°C.
  • the reduction of nitro group is done using palladium on carbon as catalyst.
  • Compound of formula 12 is produced by subjecting compound of formula 11 to diazotization in aqueous solution of hydrobromic acid, then allowing the resultant reaction mixture to react with methyl acrylate to form the ⁇ -bromo ester of formula 12 in presence of copper catalysts.
  • Compound of formula 12 needs to be purified by chromatography before subjecting to further reaction.
  • Compound of formula 12 is then allowed to react with thiourea to give compound of formula -13.
  • the reaction is carried out in methanol or isopropanol, at high temperature of around 80-100°C.
  • Compound - 12 is generally subjected to hydrolysis without isolation to form Pioglitazone hydrochloride 7.
  • p-Fluoro nitrobenzene is known to dimerize under the conditions described in the publications. Formation of impurities due to dimerization of fluoro nitrobenzene are difficult to isolate making such processes unattractive.
  • 2-(2-pyridyl)ethyl alkane sulfonate compound of formula-8 in Scheme-3 is reacted with p-hydroxy benzaldehyde in a suitable solvent selected from aliphatic halogenated hydrocarbons, aromatic hydrocarbons, ethers, water, ethyl acetate and dimethyl formamide or in a suitable mixture of them in the present of a base.
  • a suitable solvent selected from aliphatic halogenated hydrocarbons, aromatic hydrocarbons, ethers, water, ethyl acetate and dimethyl formamide or in a suitable mixture of them in the present of a base.
  • U.S. Patent No. 6, 100, 403 describes a process where attempt has been made to overcome drawbacks of earlier processes by employing ethanol or isopropanol for the condensation of p-hydroxy benzaldehyde with 5-ethylpyridine-2-ethanol and the subsequent condensation of the aldehyde derivative in toluene or ethyl acetate.
  • This approach significantly reduces the formation of 2-vinyl pyridine.
  • the major draw back in the process described is the reduction of compound of formula - 5 in Scheme-3, viz.
  • U. S. Pat. No. 5,585,495 discloses an attempt to circumvent the high-pressure reduction of double bond in compound -5 in Scheme-3 using sodium borohydride, cobalt salts like cobaltous chloride or cobaltous di acetate and dimethyl glyoxime as a ligand meant for complexing their metal ion.
  • the yields in this process are inconsistent.
  • the work up is cumbersome and requires the isolation of cobalt salts. The process has not found favor for industrial use.
  • Drugs of Future., 9, (1991), 16, 9, discloses a multi step process via carbon alkylation for the preparation of thiazoiidinedione.
  • the present invention i s a step i n the desired direction as it provides method for the preparation of pharmaceutically active compounds, such as thiazoiidinedione derivatives including Pioglitazone, Cgiitazone, Englitazone and Rosiglitazone etc and their pharmaceutically acceptable salts.
  • the invention further provides for high yielding process for the preparation of Pioglitazone intermediates and subsequent conversion to Pioglitazone hydrochloride without resorting to extensive and cumbersome purification procedures.
  • the main object of the present invention is to provide a novel method for the preparation of thiazoiidinedione derivatives of formula including their pharmacologically acceptable salts such as the acid salts including hydrochloride, hydro bromide, sulfate, organic acid salts like succinate, maleate, fumarate, laclate, tartrate, sulfonates like methane s ulfonates, toluene sulfonates, benzene sulfonates and basic salts including alkali metal salts such as the sodium salt, potassium salt, alkaline earth metal salts like calcium salt etc.
  • salts such as the acid salts including hydrochloride, hydro bromide, sulfate, organic acid salts like succinate, maleate, fumarate, laclate, tartrate, sulfonates like methane s ulfonates, toluene sulfonates, benzene sulfonates and basic salts including alkali metal salt
  • Another object of the present invention is to provide method for the preparation of such compounds having desirable pharmacological activity, broad safety margins, without toxicity or unfavorable side reaction.
  • Yet another object of the invention is to provide process for the preparation of a compound of the general formula 10A by employing readily available raw materials like p-nitro phenol as the reagent.
  • Another object of the present invention is to provide efficient and high yielding process for the converting the nitro group in general formula 10A to the corresponding amino group under controlled reduction using effective catalysts.
  • Yet another object of the p resent i nvention is to provide a method for converting the compound of general formula-13A to compound of general formula-7A by hydrolysis using mineral acid and with/without employing any other organic liquid or alcoholic solvents as co solvents.
  • Yet another object of the invention is to provide efficient and cost effective process for preparation of pioglitazone hydrochloride.
  • Another object of the present invention is to provide a commercially viable process for the preparation of pharmaceutically acceptable salts of thiazoiidinedione and the like. It may be noted that 'R' may vary from n-alkyl, acyl, aryl, heteroaryl or trifluormethyl groups.
  • R is alkyl, acyl, aryl, heteroaryl or trifluormethyl.
  • the present invention provides a process for preparing a compound of the formula-10, by reacting 2-(5-ethyl-2-pyridyl) ethyl-p-methyl sulfonate of formula -8, with p-nitro phenol in an organic solvent comprising of any aromatic hydrocarbons e.g. Toluene, xylene or benzene or any aliphatic nitriles like acetonitrile, propionitrile etc or any aprotic solvent like dimethyl formamide or dimethyl sulfoxide, the preferred solvent being aliphatic nitriles, especially acetonitrile.
  • an organic solvent comprising of any aromatic hydrocarbons e.g. Toluene, xylene or benzene or any aliphatic nitriles like acetonitrile, propionitrile etc or any aprotic solvent like dimethyl formamide or dimethyl sulfoxide, the preferred solvent being aliphatic nitriles
  • the reaction is carried out in presence of an inorganic base selected from any alkali metal carbonates, bicarbonates like sodium, potassium carbonate or bicarbonate or alkaline earth metal carbonates like calcium carbonate preferably potassium carbonate.
  • the reaction is generally conducted at elevated temperature ranging from about 20 to about 80°C, preferably from about 30 to about 50°C.
  • the compound thus prepared is isolated using aromatic hydrocarbon solvents like toluene, benzene or xylene and purified using an aliphatic solvent selected from pentane, hexane or heptanes and ethers like isopropyl ether or diethyl ether. Resulting in the pure nitro compound without resorting to extensive recrystallization or chromatography.
  • the compound of formula 10 is converted to compound of formula 11, by reduction of the nitro group by catalytic hydrogenation using Raney Nickel.
  • the reduction can also be carried out using conventional reagents like iron / hydrochloric acid, sodium hydrogen sulfide, or even sodium sulfide.
  • the catalyst of choice being Raney Nickel processed from Nickel Aluminum alloy with Ni content of 90-92% and aluminum content of 8-10% and particle sizes of the catalyst from about 150 to about 250 mesh for the controlled reduction of nitro group without affecting the more reactive pyridine ring.
  • the hydrogen pressure is of about 3kg/cm 3 to about 5kg/cm 3 , preferably of about 3kg/cm 3 to about 4kg/cm 3 .
  • the medium for hydrogenation is selected from a range of aliphatic alcohols such as methyl alcohol, ethyl alcohol, isopropyl alcohol, butyl alcohol, etc preferably methanol.
  • the amine thus obtained can be isolated by evaporation of solvent , and subjected to subsequent reaction without resorting to exhaustive purification.
  • Compound of formula 12 is prepared by conventional Meerwein Arylation step, by diazotization of the compound of formula 11 in presence of aqueous hydrogen bromide and allowing the resultant diazo compound to react with acrylic acid or its lower alkyl ester in presence of copper catalyst.
  • the compound thus obtained is purified by preferential extraction and water wash.
  • Compound of formula 12 is reacted with thiourea in presence of sodium or potassium acetate by any of the generally used methods.
  • the imino thiazolidiene of formula 13 is hydrolyzed to pioglitazone base using any of the mineral acids selected form hydrochloric, sulfuric or even hydrobromic.
  • the quantity of acid used range from about 1M to about 4M, preferably about 2M to about 3M with respect to the pioglitazone base.
  • the base thus obtained is purified to pharmaceutical grade in a variety of solvents starting from DMF/water to other aliphatic solvents like ethyl acetate.
  • the Pioglitazone base thus obtained needs to be converted to its hydrochloride salt in any alcoholic solvents using dry hydrogen chloride.
  • the process of this invention substitutes the expensive raw materials like p-fluoro nitro benzene or p-fluoro benzo nitrile as described in the prior art for the preparation of the amino compound required for building up the thiazoiidinedione ring.
  • the method also avoids cumbersome and difficult reduction of double bond in compounds known by the formula 5 in Scheme 3.
  • the preparation of other salts of pioglitazone can be achieved by the reaction of compound of formula 13 with various mineral acids like hydrochloric acid, sulfuric acid, or organic acids like methane sulfonic acid or maleic acid or fumaric acid etc.
  • the thiazolidinone base is taken in an organic solvent such as aliphatic alcohol preferably methanol, ethanol or isopropanol in molar ratio of minimum 1 :1 with respect to the thiazolidinone base.
  • organic solvent such as aliphatic alcohol preferably methanol, ethanol or isopropanol in molar ratio of minimum 1 :1 with respect to the thiazolidinone base.
  • the reaction mixture is refluxed to dissolve the thiazolidinone base and the temperature is maintained for 1 h then cooled to room temperature and further to about 10°C.
  • the precipitated solid is filtered and washed with an aliphatic alcohol such as isopropyl alcohol and dried at 50°C to obtain thiazolidienedione acid salt as a white solid.
  • the material from the previous step mixed with dioxane (225ml) and heated to dissolve the material followed by addition of activated carbon and refluxing for 1 hr.
  • the charcoal is filtered off u nder hot conditions and the solution is cooled to 0 °C over a period of 1h.
  • the precipitate is filtered and washed with dioxane, and finally with water followed by drying at 75°C -80, °C to obtain pioglitazone base (33.0g, 88%), m.p. 183- 184 °C.
  • the pioglitazone base (21.0g, 0.06 nriol) is heated with 1 N hydrochloric acid (126ml) to

Abstract

Method of obtaining anti diabetic agent of formula (7A) where in R=alkyl, aryl, heteroaryl, or trifluoromethyl as per the reaction scheme wherein the corresponding pyridine base of general formula (8A), where in Z is a leaving group other than halogen with p-nitro phenol (9) under basic conditions, followed by (a) catalytically reducing the nitro group in compound of general formula (10A) with hydrogen (b) diazotizing the amino group present in the organic residue (11A) (c) converting the diazotized residue into a derivative of 2-halopropionate of general formula (12A) following Meerwein arylation using acrylate ester (d) cyclizing the derivative of 2-halopropionate of formula (12A), with thiouriea (e) hydrolizing the resulting imine (13A), thus giving thiazolidinedione of general formula (7A) as an antidiabetic agent, in particular pioglitazone where R=ethyl in (7A).

Description

IMPROVED PROCESS FOR PREPARATION OF THIAZOLIDINEDIONE
DERIVATIVES Field of Invention
The present invention provides a novel method for preparation of Thiazoiidinedione derivatives including pioglitazone, cgiitazone, englitazone and rosiglitazone and their pharmaceutically acceptable salts
Background of the Invention
The preparation of thiazoiidinedione derivative especially pioglitazone hydrochloride is described in various publications and patents. A brief discussion of the relevant prior art is given below.
Y. Momose et al in Chem. Pharm. Bull; 39, 1440, (1991), K. Meguro et al. in the Japanese Patent No., 139182 and the article in Chem. Abstr. 109: 6504h, (1988) describe a process for making thiazoiidinedione derivative including pioglitazone based on Scheme-1 Scheme-1
Figure imgf000003_0001
Figure imgf000003_0002
Figure imgf000003_0003
Figure imgf000004_0001
Figure imgf000004_0002
Figure imgf000004_0003
The yields are generally <50%. The conversion of the nitrile to aldehyde involves reduction with Raney Nickel alloy in formic acid a reaction that is cumbersome and hazardous. The yield of the reduced product is as low as 30%. Further the conversion of compound 5 in Scheme-1, i.e. 5-[4-(2-(5-ethyl-2-pyridyl) ethoxy]benzylidene]2.4- thiazolidinedione to Pioglitazone base is effected in DMF as solvent using palladium black catalyst. The reaction requires hydrogen pressure of 50kg/cm2 and a temperature in the range of 50-60°C. These operations are low yielding (<20%), cumbersome, hazardous using expensive raw materials such as palladium and therefore remain unattractive to the industry.
D. A. Clark et al., in J. Med Chem 34, 319-325, (1991), describe a process for making substituted dihydropyran and dihydrobenzofuran thiazoiidinedione including Englitazone. This reaction process involves reduction of double bond using palladium on carbon in acetic acid as solvent. The reaction gives low yield of pioglitazone in pure form (<10%) and the product is contaminated with material obtained from the reduction of pyridine ring that are difficult to separate. K. Meguro et al., in U. S. Pat. No. 4, 687, 777, Sohda. T. et al., in 'Arznecna-Forsch (ARZANAD), 40(1), 37-42 (19910), and the patent EP 193256 describe the synthesis of Pioglitazone as per Scheme-2.
SCHEME - 2
Figure imgf000005_0001
15
Figure imgf000005_0002
10
Figure imgf000005_0003
11
Figure imgf000005_0004
12
Figure imgf000005_0005
13
Figure imgf000005_0006
Following Scheme-2, compound represented by formula -7, is prepared by subjecting compound represented by formula-13, to hydrolysis. This reaction is carried out in a solvent using mineral acid. The solvents of choice are alcohols e.g. methanol, ethanol, propanol, butanol, isobutanol, 2-methoxy ethanol etc, dimethyl sulfoxide, sulfolane, dioxane and tetrahydrofuran, dimethoxy ethane etc., and the mineral acid used are hydrochloric acid, sulfuric acid, hydrobromic acid, etc. The reaction temperature ranges from 20-150°C with the process taking up to 20 hours. The reaction for producing compound of formula 10 from compound of formula 1 is carried out with sodium hydride and in solvent like dimethyl formamide or tetrahydrofuran at temperatures ranging from -10 to 30°C. The reduction of nitro group is done using palladium on carbon as catalyst. Compound of formula 12 is produced by subjecting compound of formula 11 to diazotization in aqueous solution of hydrobromic acid, then allowing the resultant reaction mixture to react with methyl acrylate to form the α -bromo ester of formula 12 in presence of copper catalysts. Compound of formula 12 needs to be purified by chromatography before subjecting to further reaction. Compound of formula 12 is then allowed to react with thiourea to give compound of formula -13. The reaction is carried out in methanol or isopropanol, at high temperature of around 80-100°C. Compound - 12, is generally subjected to hydrolysis without isolation to form Pioglitazone hydrochloride 7.
p-Fluoro nitrobenzene is known to dimerize under the conditions described in the publications. Formation of impurities due to dimerization of fluoro nitrobenzene are difficult to isolate making such processes unattractive.
Other methods for the preparation of derivatives of thiazoiidinedione are given in publications JPA-S63 (1988)-139182; EP-A-257781 ; Chem. Pharm. Bull., 39, 1440, (1991 ); JP-A H5 (1993)-112483; and EP-A 506273 represented by scheme-3.
SCHEME- 3
Figure imgf000006_0001
8
Figure imgf000006_0002
4
J
Figure imgf000007_0001
Figure imgf000007_0002
Figure imgf000007_0003
Here 2-(2-pyridyl)ethyl alkane sulfonate compound of formula-8 in Scheme-3 is reacted with p-hydroxy benzaldehyde in a suitable solvent selected from aliphatic halogenated hydrocarbons, aromatic hydrocarbons, ethers, water, ethyl acetate and dimethyl formamide or in a suitable mixture of them in the present of a base. When the reaction is conducted in non-aqueous organic solvent the reaction takes approximately 25-30h. for completion. Due to β-elimination reaction as the side reaction, 2-vinyl pyridine is produced thereby lowering the yield and purity of the benzaldehyde compound in subsequent reaction steps. If the reaction needs to be conducted in aqueous and non- aqueous solvent, a phase transfer catalyst is required. The formation of thick s lurry creates problems of inhomogeneous mixing thereby affecting the yield (as low 50-60%) and purity of the benzaldehyde compound 4. Further the reduction of double bond in the compound of formula 5 in Scheme-3 requires expensive noble metal catalysts, high pressure and high temperature. The process described as per Scheme-3 has serious limitations for industrial application.
U.S. Patent No. 6, 100, 403 describes a process where attempt has been made to overcome drawbacks of earlier processes by employing ethanol or isopropanol for the condensation of p-hydroxy benzaldehyde with 5-ethylpyridine-2-ethanol and the subsequent condensation of the aldehyde derivative in toluene or ethyl acetate. This approach significantly reduces the formation of 2-vinyl pyridine. The major draw back in the process described is the reduction of compound of formula - 5 in Scheme-3, viz. 5-[4-[2-(ethyl-2-pyridyl) ethoxy] benzylidene] 2,4-thiazolidinedione using palladium on carbon as catalyst is that it requires hydrogen pressure of 50 kg/cm and temperature of 110°C for 5 hours for completion of the reduction. The yield obtained is about 66% with substantial quantities of impurities that need extensive purification. The high hydrogen pressures and temperatures used in this reaction make this process unsuitable for effective industrial use.
U. S. Pat. No. 5,585,495 discloses an attempt to circumvent the high-pressure reduction of double bond in compound -5 in Scheme-3 using sodium borohydride, cobalt salts like cobaltous chloride or cobaltous di acetate and dimethyl glyoxime as a ligand meant for complexing their metal ion. The yields in this process are inconsistent. The work up is cumbersome and requires the isolation of cobalt salts. The process has not found favor for industrial use.
Several references disclose cobalt catalyzed reduction of compound 5 -[4-(2-(~5-ethyl- 2pyridyl ethoxy] benzylidene] 2,4-thiazolidinedione, prepared by the condensation of 5- ethyl pyridine-2-ethanol with p-hydroxy benzaldehyde following Scheme-3. [Ref; U. Leuteneggar., Agnew. Chem Int Ed. Eng., 28:60, 1989, M. Ricroch et al., J. org. met Chem., 67, 119, (1974); J. O. Oshy et a., JACS, 108, 67-72, (1986). These methods have the inherent disadvantage of preparing cobalt complexes of sodium borohydride either with semicorrin, pyridinato cobaloxime, chloro pyridinato cobaloxime or Vitamin B 12. Reductions have also been reported using lithium aluminum hydride.
Drugs of Future., 9, (1991), 16, 9, discloses a multi step process via carbon alkylation for the preparation of thiazoiidinedione.
All the processes described in the prior art are cumbersome needing extensive workup with high pressures/temperatures, low yielding, hazardous, expensive and therefore remain unattractive for industrial use.
It has been a long-standing need of the industry to develop industrially viable processes that are cost effective, simple, efficient and safe to implement in the industrial scale.
The present invention i s a step i n the desired direction as it provides method for the preparation of pharmaceutically active compounds, such as thiazoiidinedione derivatives including Pioglitazone, Cgiitazone, Englitazone and Rosiglitazone etc and their pharmaceutically acceptable salts. The invention further provides for high yielding process for the preparation of Pioglitazone intermediates and subsequent conversion to Pioglitazone hydrochloride without resorting to extensive and cumbersome purification procedures.
Objects of the invention
The main object of the present invention is to provide a novel method for the preparation of thiazoiidinedione derivatives of formula including their pharmacologically acceptable salts such as the acid salts including hydrochloride, hydro bromide, sulfate, organic acid salts like succinate, maleate, fumarate, laclate, tartrate, sulfonates like methane s ulfonates, toluene sulfonates, benzene sulfonates and basic salts including alkali metal salts such as the sodium salt, potassium salt, alkaline earth metal salts like calcium salt etc.
Another object of the present invention is to provide method for the preparation of such compounds having desirable pharmacological activity, broad safety margins, without toxicity or unfavorable side reaction.
Yet another object of the invention is to provide process for the preparation of a compound of the general formula 10A by employing readily available raw materials like p-nitro phenol as the reagent.
Another object of the present invention is to provide efficient and high yielding process for the converting the nitro group in general formula 10A to the corresponding amino group under controlled reduction using effective catalysts.
Figure imgf000009_0001
Yet another object of the p resent i nvention is to provide a method for converting the compound of general formula-13A to compound of general formula-7A by hydrolysis using mineral acid and with/without employing any other organic liquid or alcoholic solvents as co solvents.
Figure imgf000010_0001
13A
Yet another object of the invention is to provide efficient and cost effective process for preparation of pioglitazone hydrochloride.
Figure imgf000010_0002
7A
Another object of the present invention is to provide a commercially viable process for the preparation of pharmaceutically acceptable salts of thiazoiidinedione and the like. It may be noted that 'R' may vary from n-alkyl, acyl, aryl, heteroaryl or trifluormethyl groups.
Summary of the invention;
The process of this invention is illustrated in Scheme-4
SCHEME 4
Figure imgf000011_0001
where R is alkyl, acyl, aryl, heteroaryl or trifluormethyl.
In accordance with this invention the process of preparation of thiazoiidinedione derivatives and their pharmaceutically acceptable salts comprise
• reacting 2-(5-R-2-pyridine) ethyl methane sulfonate of general formula 8A, where R is alkyl, aryl, aryl or heteroaryl with p-nitro phenol in an organic solvent and in presence of suitable base
• Conversion of the adduct thus obtained viz. 4-(2-(5-R-pyridine) ethoxy nitro benzene of general formula 10A to the corresponding amine by catalytic reduction employing noble metal catalysts or Raney nickel and hydrogen. • The amine viz. 4-(2-(5-R-pyridine) ethoxyaniline of general formula 11A is diazotized in a manner known to those skilled in the art. The diazo compound is allowed to undergo Meerwein arylation using ethyl acrylate to obtain 2-bromo-3- (4-2-5-R-2-pyridyl) ethoxyphenyl) propionate of general formula 12A. • The Meerwein arylated product 12A is allowed to react with thiourea in situ with out isolation of 12A to give the imino thiazolidinone viz. 5-(4-(2-(5-R-2-pyridyl) ethoxy) benzyI-2-imino-4-thiazolidinone of general formula 13A.
• The imino thiazolidinone under suitable acidic condition is converted to the thiazoiidinedione derivative represented by the general formula 7A. • When R=ethyl (C2H5), in formula 7A and using dilute hydrochloric acid, the imino thiazolidinone 13A is converted to pioglitazone hydrochloride.
Detailed Description of the Invention
The process as per scheme-4 is described in detail for pioglitazone hydrochloride where R is ethyl (CH2CH3) as a preferred embodiment.
The present invention provides a process for preparing a compound of the formula-10, by reacting 2-(5-ethyl-2-pyridyl) ethyl-p-methyl sulfonate of formula -8, with p-nitro phenol in an organic solvent comprising of any aromatic hydrocarbons e.g. Toluene, xylene or benzene or any aliphatic nitriles like acetonitrile, propionitrile etc or any aprotic solvent like dimethyl formamide or dimethyl sulfoxide, the preferred solvent being aliphatic nitriles, especially acetonitrile. The reaction is carried out in presence of an inorganic base selected from any alkali metal carbonates, bicarbonates like sodium, potassium carbonate or bicarbonate or alkaline earth metal carbonates like calcium carbonate preferably potassium carbonate. The reaction is generally conducted at elevated temperature ranging from about 20 to about 80°C, preferably from about 30 to about 50°C. The compound thus prepared is isolated using aromatic hydrocarbon solvents like toluene, benzene or xylene and purified using an aliphatic solvent selected from pentane, hexane or heptanes and ethers like isopropyl ether or diethyl ether. Resulting in the pure nitro compound without resorting to extensive recrystallization or chromatography.
The compound of formula 10 is converted to compound of formula 11, by reduction of the nitro group by catalytic hydrogenation using Raney Nickel. The reduction can also be carried out using conventional reagents like iron / hydrochloric acid, sodium hydrogen sulfide, or even sodium sulfide. The catalyst of choice being Raney Nickel processed from Nickel Aluminum alloy with Ni content of 90-92% and aluminum content of 8-10% and particle sizes of the catalyst from about 150 to about 250 mesh for the controlled reduction of nitro group without affecting the more reactive pyridine ring. The hydrogen pressure is of about 3kg/cm3 to about 5kg/cm3, preferably of about 3kg/cm3 to about 4kg/cm3. The medium for hydrogenation is selected from a range of aliphatic alcohols such as methyl alcohol, ethyl alcohol, isopropyl alcohol, butyl alcohol, etc preferably methanol. The amine thus obtained can be isolated by evaporation of solvent , and subjected to subsequent reaction without resorting to exhaustive purification.
Compound of formula 12 is prepared by conventional Meerwein Arylation step, by diazotization of the compound of formula 11 in presence of aqueous hydrogen bromide and allowing the resultant diazo compound to react with acrylic acid or its lower alkyl ester in presence of copper catalyst. The compound thus obtained is purified by preferential extraction and water wash.
Compound of formula 12 is reacted with thiourea in presence of sodium or potassium acetate by any of the generally used methods. The imino thiazolidiene of formula 13 is hydrolyzed to pioglitazone base using any of the mineral acids selected form hydrochloric, sulfuric or even hydrobromic. The quantity of acid used range from about 1M to about 4M, preferably about 2M to about 3M with respect to the pioglitazone base. The base thus obtained is purified to pharmaceutical grade in a variety of solvents starting from DMF/water to other aliphatic solvents like ethyl acetate. The Pioglitazone base thus obtained needs to be converted to its hydrochloride salt in any alcoholic solvents using dry hydrogen chloride.
The process of this invention substitutes the expensive raw materials like p-fluoro nitro benzene or p-fluoro benzo nitrile as described in the prior art for the preparation of the amino compound required for building up the thiazoiidinedione ring. The method also avoids cumbersome and difficult reduction of double bond in compounds known by the formula 5 in Scheme 3.
Furthermore, the preparation of other salts of pioglitazone can be achieved by the reaction of compound of formula 13 with various mineral acids like hydrochloric acid, sulfuric acid, or organic acids like methane sulfonic acid or maleic acid or fumaric acid etc.
In the case of the organic acids, the thiazolidinone base is taken in an organic solvent such as aliphatic alcohol preferably methanol, ethanol or isopropanol in molar ratio of minimum 1 :1 with respect to the thiazolidinone base. The reaction mixture is refluxed to dissolve the thiazolidinone base and the temperature is maintained for 1 h then cooled to room temperature and further to about 10°C. The precipitated solid is filtered and washed with an aliphatic alcohol such as isopropyl alcohol and dried at 50°C to obtain thiazolidienedione acid salt as a white solid.
The present invention is illustrated by means of following non-limiting examples.
Example - 1:
Preparation of 4-(2-(5-ethyl-pyridine) ethoxy) nitrobenzene
p-Nitro phenol (57.45g, 0.42mol), acetonitrile (450ml) and potassium carbonate (67.80, 0.488 mol) are mixed and heated to 60°C. 2-(5-ethyl-2-pyridine)ethylmethanesulfonate (85.95, 0.375 mol) in acetonitrile (75ml) is added to the above solution over a period of 2h. The resulting reaction mixture is heated under stirring for 5-6hrs. After completion of the reaction, the system is cooled to room temperature and filtered. The filtrate is collected and the acetonitrile is removed under vacuum. The residue thus obtained is dissolved in ethyl a cetate and the ethyl acetate layer is washed with water and then with 10% sodium hydroxide solution and finally with water. The solvent is removed under vacuum and the residue is taken in petroleum ether (300ml) and heated to 50°C. Activated charcoal is added at this stage and filtered to obtain a clear solution. The solution is cooled to 0-5°C under stirring and filtered. The solid obtained i s dried at room temperature in air to obtain the product (50.0g, 47.0%). The compound is re- crystallized from ethyl acetate -hexane to give colorless prisms, m. p. 53-55°C.
Example -2:
Preparation of 4-(2-(5-ethyl-2-pyridyl)ethoxy aniline
In a stainless steel autoclave 4-(2-(5-ethyl-2-pyridyl)ethoxy)nitrobenzene (500g, 6.94 m mol) is charged in methanol (2500 ml) followed by Raney Nickel (5.00g dry weight) and stirred for 10-15 min. The system is charged with hydrogen to a pressure of 4kg/cm2 and the reaction is carried out in the stirred autoclave for 8-10 hours or until the reduction of nitro compound to amino compound is completed as indicated by HPLC or TLC.
After the completion of the reaction, the residual hydrogen is vented off and the autoclave is pressurized with nitrogen. After venting the nitrogen, the solution is filtered to remove the Raney nickel. The filtrate is concentrated under vacuum at 40-45°C. The product is collected as pale yellow oil. Yield 430g (97%)
Example - 3:
Preparation of 2-bromo-3 — [4-2-5-ethyl-2-pyridyl) ethoxy phenyl propionate
4-(2-(5-ethyI-pyridine) ethoxy) aniline (73.0g, 0.3mol) in a mixture of acetone/water (8:3) {1050 ml} is cooled to 0°C. 48% hydrobromic acid (225g) is added slowly so as to keep the temperature below 5°C. On completion of the addition of hydrobromic acid the reaction mixture is stirred for 30min and aqueous solution of sodium nitrate (25.0g, 0.36 mol) is slowly added. The reaction mixture is maintained at 0-5°C for 2hr and methyl acrylate (153g, 1.8 mol) is added. The reaction mixture is slowly brought to room temperature under stirring. The reaction mixture is heated to 40°C and portions of cuprous oxide (3.0g, 0.021 mol) are slowly added in a period of 1-3 hr. After the addition is completed stirring is continued for 2-3 hrs to complete the reaction.
The reaction mixture is concentrated under vacuum to remove methanol and acetone. To the residue thus obtained water is charged then cooled to 10-15°C and ammonia solution (25%) is slowly added to bring pH of the solution to 9.00. After the addition of ammonia is completed, stirring is continued for 30min. and ethyl acetate (375ml) is added followed by separation of the layers. The aqueous layer is extracted few times with ethyl acetate and combined with the organic layer. The organic layer is washed with water a nd the acetate is d istilled off u nder vacuum to obtain the product ( 102g, 86.7%). No purification is needed at this stage. Example - 4:
Preparation of 5(4-(2-(5-ethyl-2-pyridyl) ethoxy) benzyl)-2-imino-4-thiazolidinone
To a solution 2-bromo-3-[4-2-5-ethyI-2-pyridyl) ethoxy phenyl propionate (59.0g, 0.15 mol) in methanol (450ml), thiourea (11.4 g, 0.15 mol) and sodium acetate (12.3g, 0.15 mol) is added and heated under stirring to reflux. Reflux is continued for 6-7 hrs or until the reaction is complete as indicated by TLC or HPLC. The reaction mixture is cooled to room temperature and finally to 0°C -5 °C followed by filtration of the p recipitated solid. The precipitate is washed with water (50ml X2) and finally a few times with acetone and dried at 70°C - 75 °C. (24.3g, 45.6%, HPLC purity is 98%).
Example - 5:
Preparation of Pioglitazone hydrochloride:
5(4-(2-(5-ethyl-2-pyridyl) ethoxy) benzyl)-2-imino-4-thiazolidinone (36.0g, 0.105 mol) and 2 N hydrochloric acid (300ml) is heated to reflux for 6h. After cooling to room temperature, pH of the reaction mixture is adjusted to about with aqueous sodium hydroxide solution. The precipitated solid is filtered and washed with water and dried at 75°C - 80 °C. (35.0g).
The material from the previous step mixed with dioxane (225ml) and heated to dissolve the material followed by addition of activated carbon and refluxing for 1 hr. The charcoal is filtered off u nder hot conditions and the solution is cooled to 0 °C over a period of 1h. The precipitate is filtered and washed with dioxane, and finally with water followed by drying at 75°C -80, °C to obtain pioglitazone base (33.0g, 88%), m.p. 183- 184 °C.
The pioglitazone base (21.0g, 0.06 nriol) is heated with 1 N hydrochloric acid (126ml) to
80 °C under stirring until the material dissolves completely. The heating is continued for 1h and the solution is filtered to remove any u ndissolved m aterial. The filtrate is heated again to 80 °C and maintained at that temperature for 1h and finally cooled to room temperature and further to about 10°C. The precipitated solid is filtered and washed with isopropyl alcohol (3X20ml) and dried at 50 ° to obtain pioglitazone hydrochloride as a white solid (20.5g, 87%).

Claims

Claims:We claim
1. A process is for the preparation of Thiazoiidinedione derivatives of general formula 5- (4-(2-(5-R-2-pyridyl) ethoxy) benzyl-2-imino-4-thiazolidinone including pioglitazone, cgiitazone, englitazone and rosiglitazone and their pharmaceutically acceptable salts of general formula 5-(4-(2-(5-R-2-pyridyl) ethoxy) benzyl-2, 4-thiazolidinienedione.X, where R is alkyl, acyl, aryl, heteroaryl or trifluormethyl and X is a mono acid, comprising steps
• reacting 2-(5-R-2-pyridine) ethyl methane sulfonate , where R is alkyl, acyl, aryl or heteroaryl with p-nitro phenol in an organic solvent and in presence of suitable base
• Conversion of the adduct thus obtained viz. 4-(2-(5-R-pyridine) ethoxy nitro benzene to the corresponding amine by catalytic reduction employing noble metal catalysts or Raney nickel and hydrogen in an appropriate solvent
• Diazotization of the amine viz. 4-(2-(5-R-pyridine) ethoxyaniline
• Meerwein arylation of the diazo compound using ethyl acrylate to obtain 2- bromo-3- (4-2-5-R-2-pyridyl) ethoxyphenyl) propionate • Reaction of the Meerwein arylated product with thiourea to give the imino thiazolidinone viz. 5-(4-(2-(5-R-2-pyridyl) ethoxy) benzyl-2-imino-4-thiazolidinone
• Conversion of the imino thiazolidinone under acidic condition to the corresponding thiazoiidinedione salt
2. A process wherein reaction of p-nitro phenol with 2-(5-R-2-pyridine) ethyl methane sulfonate is carried out in an organic solvent selected from aromatic hydrocarbon, such as toluene, xylene, benzene or any aliphatic nitriles such as acetonitrile, propionitrile etc or any aprotic solvent like dimethyl formamide or dimethyl sulfoxide, the preferred solvent being aliphatic nitriles, especially acetonitrile. aliphatic nitriles, aliphatic amides and sulfoxide in the presence of suitable base at temperatures ranging from 20°C - 80°C preferably between 30°C to 50°C, the base being selected from alkali or alkaline earth metals, preferably their carbonates or bicarbonates and the product of the reaction being separated using aromatic hydrocarbon solvents like toluene, benzene or xylene and purified using an aliphatic solvent selected from pentane, hexane or heptanes and ethers like isopropyl ether or diethyl ether.
3. A process as claimed in claims 1-2 wherein the base is preferably potassium carbonate.
4. A process for the conversion of the adduct 4-(2-(5-R-pyridine) ethoxy nitro benzene to the corresponding amine by catalytic reduction Raney nickel and hydrogen wherein the catalyst of choice being Raney nickel processed from Nickel Aluminum alloy with Ni content of 90-92% and aluminum content of 8-10% and particle sizes of the catalyst from about 150 to about 250 mesh.
5. A process as claimed in claim 1 and 4 wherein the hydrogenation is carried out in organic solvents selected from aliphatic alcohols such as methyl alcohol, ethyl alcohol, isopropyl alcohol, butyl alcohol, and the preferable solvent being methanol.
6. The hydrogenation in the process as claimed in claims 1 , 4 and 5 wherein the pressure of hydrogen is about 3kg/cm3 to about 5kg/cm3, preferably of about
3kg/cm3 to about 4kg/cm3.
7. The reduction as claimed in claim 1 is optionally carried out using iron / hydrochloric acid, sodium hydrogen sulfide, or sodium sulfide.
8. A process wherein the amine viz. 4-(2-(5-R-pyridine) ethoxyaniline is diazotized and the diazo compound is allowed to undergo Meerwein arylation in aqueous hydrogen bromide and allowing the resultant diazo compound to react with acrylic acid or its lower alkyl ester such as ethyl acrylate in presence of copper catalyst to obtain 2- bromo-3- (4-2-5-R-2-pyridyl) ethoxyphenyl) propionate which is purified by preferential extraction and water wash.
9. A process for the reaction of the Meerwein arylated product with thiourea to give the imino thiazolidinone in presence of sodium or potassium acetate and further hydrolyzed to thiazolidinone base using any of the mineral acids selected form hydrochloric, sulfuric or even hydrobromic acid in any alcoholic solvents.
10. A process as claimed in claim 1 wherein the thiazolidinone base is converted to the corresponding organic acid salts such as the succinate, maleate, fumarate, laclate, tartrate, sulfonates like methane sulfonates, toluene sulfonates, benzene sulfonates with various organic acids such as succinic acid, maelaic acid, fumaric acid, lactic acid, tartaric acid, methane sulfonic acid para toulene sulphonic acid etc respectively.
11. A process as claimed in claims 1 and 10 wherein the thiazolidinone base is converted to the corresponding organic acid salts by refluxing the organic acid with the thiazolidinone base with in molar ratio of minimum 1:1 with respect to the thiazolidinone base in an organic solvent such as aliphatic alcohol preferably methanol, ethanol or isopropanol for a period of at least 1 hr followed by cooling to about about 10°C, filtering, washing of the product with an aliphatic alcohol such as isopropyl alcohol and drying at around 50°C to obtain thiazoiidinedione acid salt.
12. A process as claimed in claim 1 and 9 -10 wherein the acid used range from about 1 M to about 4 M, preferably about 2 M to about 3 M with respect to the thiazolidinone base.
13. A process as claimed in claim 1 and 9 wherein the thiazolidinone base is purified to pharmaceutical grade using solvents selected from starting from DMF/water mixtures, aliphatic solvents such as ethyl acetate.
14. Process for preparation of pioglitazone hydrochloride and the mineral acid used is dilute hydrochloric acid for the conversion of imino thiazolidinone where R=ethyl to pioglitazone hydrochloride.
PCT/IB2003/003858 2002-09-12 2003-08-29 Improved process for preparation of thiazolidinedione derivatives WO2004024059A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003260813A AU2003260813A1 (en) 2002-09-12 2003-08-29 Improved process for preparation of thiazolidinedione derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN823/MUM/2002 2002-09-12
IN823MU2002 2002-09-12

Publications (2)

Publication Number Publication Date
WO2004024059A2 true WO2004024059A2 (en) 2004-03-25
WO2004024059A3 WO2004024059A3 (en) 2004-11-04

Family

ID=31986002

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/003858 WO2004024059A2 (en) 2002-09-12 2003-08-29 Improved process for preparation of thiazolidinedione derivatives

Country Status (2)

Country Link
AU (1) AU2003260813A1 (en)
WO (1) WO2004024059A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006035459A1 (en) * 2004-09-28 2006-04-06 Morepen Laboratories Limited An improved process for the production of derivatives of thiozolidinediones and their precursors
WO2006117654A1 (en) * 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Processes for the preparation of pioglitazone or salts thereof
JP2009190991A (en) * 2008-02-13 2009-08-27 Tokuyama Corp Method for producing 5-{4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl}-2-imino-4-thiazolidinone
JP2009196936A (en) * 2008-02-21 2009-09-03 Tokuyama Corp Method for producing methyl 2-bromo-3-{4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl}propionate
JP2010059068A (en) * 2008-09-02 2010-03-18 Tokuyama Corp Method of producing pioglitazone
JP2010208957A (en) * 2009-03-06 2010-09-24 Tokuyama Corp 5-{4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl}-2-imino-4-thiazolidinone having crystal structure and method for producing the same
WO2012153312A1 (en) 2011-05-11 2012-11-15 Ranbaxy Laboratories Limited Process for the purification of pioglitazone
CN111875598A (en) * 2020-05-23 2020-11-03 白银京宇新药业有限公司 Preparation method of pyriformimine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687777A (en) * 1985-01-19 1987-08-18 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, useful as antidiabetic agents
US5585495A (en) * 1991-12-20 1996-12-17 The Upjohn Company Reduction method for substituted 5-methylene-thiazolidinediones
US6100403A (en) * 1996-06-27 2000-08-08 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687777A (en) * 1985-01-19 1987-08-18 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, useful as antidiabetic agents
US5585495A (en) * 1991-12-20 1996-12-17 The Upjohn Company Reduction method for substituted 5-methylene-thiazolidinediones
US6100403A (en) * 1996-06-27 2000-08-08 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006035459A1 (en) * 2004-09-28 2006-04-06 Morepen Laboratories Limited An improved process for the production of derivatives of thiozolidinediones and their precursors
WO2006117654A1 (en) * 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Processes for the preparation of pioglitazone or salts thereof
JP2009190991A (en) * 2008-02-13 2009-08-27 Tokuyama Corp Method for producing 5-{4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl}-2-imino-4-thiazolidinone
JP2009196936A (en) * 2008-02-21 2009-09-03 Tokuyama Corp Method for producing methyl 2-bromo-3-{4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl}propionate
JP2010059068A (en) * 2008-09-02 2010-03-18 Tokuyama Corp Method of producing pioglitazone
JP2010208957A (en) * 2009-03-06 2010-09-24 Tokuyama Corp 5-{4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl}-2-imino-4-thiazolidinone having crystal structure and method for producing the same
WO2012153312A1 (en) 2011-05-11 2012-11-15 Ranbaxy Laboratories Limited Process for the purification of pioglitazone
CN111875598A (en) * 2020-05-23 2020-11-03 白银京宇新药业有限公司 Preparation method of pyriformimine
CN111875598B (en) * 2020-05-23 2023-10-10 白银京宇新药业有限公司 Preparation method of pioglitazone

Also Published As

Publication number Publication date
AU2003260813A1 (en) 2004-04-30
AU2003260813A8 (en) 2004-04-30
WO2004024059A3 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
CA2669069A1 (en) Process for the preparation of 2-imino-thiazolidin-4-one derivatives
US7009057B2 (en) Method for obtaining pioglitazone as an antidiabetic agent
US8168787B2 (en) Process for the preparation of imatinib and intermediates thereof
WO2004024059A2 (en) Improved process for preparation of thiazolidinedione derivatives
WO2006035459A1 (en) An improved process for the production of derivatives of thiozolidinediones and their precursors
WO2008035380A2 (en) An improved process for the preparation of high purity formoterol and its pharmaceutically acceptable salts
CZ20003109A3 (en) Process for preparing protected 4-aminomethyl-pyrrolidin-3-one
EP2146719B1 (en) Process for making galantamine
US10508110B2 (en) Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo [2,3-B]pyridin-3-yl-acetic acid
US8569483B2 (en) Process for the preparation of bazedoxifene acetate and intermediates thereof
EP0690835B1 (en) Formylation process for aromatic aldehydes
PL195482B1 (en) Method of obtaining substituted thiazolydinodione
CA2616249A1 (en) A process for the preparation of substituted phenyl ether compounds and rosiglitazone
JP4162274B2 (en) Process for producing bis (2-hydroxyphenyl-3-benzotriazole) methanes
AU2021308138A1 (en) Method for producing optically active compound
US20060229453A1 (en) Process for the preparation of 5-[4-[2-[N-methyl-N-(2-pyridyl) amino] ethoxy] phenyl methyl] thiazolidine-2,4-dione maleate (rosiglitazone)
US20050033088A1 (en) Process for the preparation of phenethylamine derivative, an intermediate of Venlafaxine hydrochloride
WO2006090264A1 (en) A process for the synthesis of 2-amino-5-protected amino-3-hydroxy-1, 6-diphenylhexane or a salt thereof - an intermediate for antiviral drugs
WO2003029251A1 (en) Novel process for the synthesis of thiazolidinedione derivatives
CN112724077B (en) Synthesis method of loratidine intermediate
US11459303B2 (en) Process for the synthesis of lofexidine
EP1496051B1 (en) Method for preparing 6-aminomethyl-6,11-dihydro-5h-dibenz(b,e)azepine
WO2008075380A2 (en) Process for the preparation of thiazolidine derivatives
US5274100A (en) Process for the preparation of (3-fluoropyridin-2-yloxy)phenoxypropionic acids
KR100697983B1 (en) Novel intermediate, manufacturing method of pioglitazone using it

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP